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Abstract
Background: Several studies have shown that in diabetic patients, the glycemic profile was disturbed after intra-
articular injection of corticosteroids. Little is known about the impact of epidural injection in such patients. The
goal of this study was double, at first comparing the glycaemic profile in diabetic patients after a unique injection
of 80 mg of acetate methylprednisolone either intra-articular or epidural and secondly to compare the amount of
systemic diffusion of the drug after both procedures.
Methods: Seventeen patients were included. Glycemic changes were compared in 9 diabetic patients following
intra-articular (4 patients) and epidural injections (5 patients).
Epidural injections were performed using the sacral route under fluoroscopic control in patients with lumbar spinal
stenosis. Diabetes control had to stable for more than 10 days and the renal function to be preserved. Blood
glucose was monitored using a validated continuous measuring device (GMS, Medtronic) the day before and for
two days following the injection. Results were expressed in the form of daily glycemic profiles and as by mean,
peak and minimal values +/- SD. The urinary excretion of methylprednisolone after the 2 routes of injection was
analyzed in 8 patients (4 in each group). Urine samples were cropped one hour before the injections, then 4 times
during the first day and 3 times a week for 2 weeks. The measurements included the free and conjugated fraction
Results: The glycaemic profile remains unchanged with no significant changes in the group of the 5 diabetic
patients receiving epidural injections.
On the other end, the average peak and and mean values were enhanced up to 3 mmol/l above baseline two
days after the infiltration in the groups of the 4 diabetic patients infiltrated intra-articular. The mean urinary
excretion of the steroid was about ten times higher in the intra-articular versus epidural group: 7000 ng/ml versus
700 ng/ml. Looking at each individual there were marked differences especially after intra-articular injections.
Conclusion: This is the first study to show that a single epidural steroid injection of 80 mg depot
methylprednisolone had no effect on the glycemic control in diabetic patients. The absence of glycemic control
changes correlated well with the very low urinary excretion of the drug after epidural injection.
Trial registration: NCT01420497
Background
Several studies [1-3] have shown that in diabetic
patients, the glycaemic profile can be profoundly dis-
turbed after an intra-articular corticosteroid injection.
The elevation of blood glucose is attributed to diffusion
of the injected drug from the joint into the systemic cir-
culation. The amount of steroids in the systemic com-
partment and the duration of local and systemic effects
are related to the solubility of the preparation, the dose
injected and probably the degree of inflammation of the
joint [3,4]. Amstrong [5] have shown that plasma steroid
levels could vary up to five times from one patient to
another following injection into the knee joint. On the
contrary, little is known about the kinetics of absorption
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steroid preparations after epidural injection. Jacob et al.
[6] suggested that very little of the drug diffused outside
the epidural space since they were not able the measure
any significant plasma concentration of the drug after
an epidural injection of 80 mg of acetate of methylpred-
nisolone. Moreover, no study has evaluated, to our
knowledge, the impact of epidural injection of an depot
steroid on the glycaemic profile in diabetic patients.
In a former study [7], we have evaluated systemic dif-
fusion of methylprednisolone, triamcilone and depot
bethametasone in 25 patients either after intra articular
or intra-muscular injections by measuring the urinary
excretion of the compounds. The mean excretion after
intra-articular was slightly lower than after intra- mus-
cular but in the same range.
Our study had two objectives. Firstly, we wished to
compare the effects on the glycaemic profile after an
injection of 80 mg of methylprednisolone acetate either
by the epidural route or intra-articularly, in diabetic
patients. Secondly, we compared the systemic diffusion
of steroids in the two procedures.
Due to the small number of patients in each group
statistics were limited to Student Test comparison.
P< 0.05 was considered as significant.
Methods
The protocole was approved by the ethical committee of
the university of Lausanne Switzerland. Seventeen non
consecutive patients and healthy subjects were included
in the study between September 2008 and May 2010.
All gave their informed consent.
Glycemic changes were compared in 9 diabetic
patients following intra-articular (4 patients) and epi-
dural injections (5 patients). The urinary excretion of
methylprednisolone after the 2 routes of injection was
analyzed in 8 patients (4 in each group). The character-
istics of the patients and the participants are summar-
ized in Table 1.
None of the patients had a renal impairment which
could interfere with renal elimination of the steroids.
The characteristics of Diabetes (duration of the illness
type of treatment were similar in both groups) Fasting
glycaemia had to be stable for at least 10 days before
steroid injection and no changes in diabetic treatment
or in life-style were permitted during the three days of
the study.
Blood glucose was measured using a continuous
device (CGMS, Medtronic, Switzerland) the day before
[day 1] and for two days following the injection. The
CGMS sensor was inserted under the abdominal skin.
For the three days, the glycaemic profile was recorded
every 5 min, and the data stored on a portable device
attached to a belt. At the end of the evaluation, the data
were transferred to a computer for analysis. The device
permitted the test subject to take part in normal daily
activities. The accuracy and reproducibility of the mea-
surements taken by the CGMS sensor have been con-
firmed [8]. Results were expressed in the form of daily
glycaemic profiles as well as by mean, peak and minimal
values +/- SD.
Eighty mg of acetate methylprednisolone [Depome-
drol
® MSD] was administered by either the intra-
articular route or by epidural injection. The same
experienced rheumatologist who was not in charge of
the diabetes made all the infiltrations. Epidural injec-
tions were performed using the sacral route under
fluoroscopic control with prior injection of contrast
agent in order to confirm the exact localisation of the
product [9]. The indications for steroid injections were
symptomatic spinal stenosis in all the patients. Intra-
articular injections were performed in patients with
either an inflammatory (3 times) or degenerative dis-
eases (3 times) in the knee (6 times) according to stan-
dard procedure and in the shoulder under ultrasound
guidance (2 times).
For urinary excretion measurements, urine samples
were collected one hour before the injection, then 4
times during the first day and finally 3 times a week for
2 weeks each two days, between 7-9 h AM the morning.
The measurements included the free and the conjugated
fraction of the injected steroid and were all performed
Table 1 Characteristics of the participants
Intra-articular injected Epidural injected
Glycaemic evaluation Urinary excretion evaluation Glycaemic evaluation Urinary excretion evaluation
Nbr analyzed 4 4 5 4
Mean age [years] (SD) 56(6) 50 (4) 65 (9) 61(6)
Sex[M/F] 3/2 2/2 3/2 2/2
Diabetic patients 4 1 5 2
Insulin treated 3 1 4 2
Mean BMI(SD) 27(6) 31(10)
Duration of the illness[years] 4 5
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to a validated and published method [7,10].
Results
At day 0, the mean blood glucose values were similar
before steroid injections in the two groups. In the group
of diabetic patients who received epidural injections, the
glycaemic profile remained unchanged with no signifi-
cant changes and very few individual differences (Figures
1 and 2). In contrast, the group of diabetic patients who
received intra-articular injections showed mean eleva-
tion of peak blood sugar levels of 3 mmol/l two days
after the infiltration (at day 3). These changes remain
however not significant compared to baseline values due
to marked individual variations (Figure 1). By cons, the
peak, and mean values after the intra-articular were at
day 3 significantly higher than after epidural injections
(p< 0.05) although the baseline values were identical in
both groups (Figure 2). No local or systemic complica-
tion or side effect following the infiltrations occurred in
both groups.
In the second part, we proceeded to analyse the urin-
ary steroid excretion after each mode of administration.
Both conjugated and free forms of methylprednisolone
were detected after intra-articular injection, with a peak
of excretion during the first 24 first hours after injec-
tions. Steroid levels were minimal after 48 h and unde-
tectable after 200 h (Figure 3) in both group. Only some
conjugated form of the product could be detected after
epidural infiltration.
For this conjugated form, the mean of highest + 3
standard deviations was about ten times higher in the
intra-articular versus epidural group: 7000 ng/ml versus
700 ng/ml (Figure 3). We noticed individual differences
in the intra-articular group, not linked to the diabetic
status. The range of excretion remained for 3 out 4 of
them much higher than after epidural infiltration. They
were no differences in the epidural group, between the
2 diabetic and the 2 non-diabetic patients. In all of
them, the excretion was much lower than after intra-
articular infiltrations (Figure 3)
Discussion and conclusions
To our knowledge, this is the first study to show that a
single epidural steroid injection of 80 mg depot methyl-
prednisolone had no effect on the glycaemic profile. Dif-
ferent results were obtained after epidural injection of
soluble betamethasone and soluble cortivazol [11,12].
The authors of this study showed a significant increase
of glycaemia in the evening following the injection. The
glycaemic profile remained also higher for two following
Figure 1 Mean peak, mean and lowest blood glucose values+/_SD evolution before and after the infiltrations.
Figure 2 Individual peak blood glucose evolutions before and
after the infiltrations.
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f e r e n c eb e t w e e nt h et w os t u d i e sc o u l db er e l a t e dt ot h e
type of steroid used [soluble versus depot steroid] which
have been shown to have different metabolism and spee-
diness of elimination in human and in experimental ani-
mal models [13].
On the contrary, intra-articular methylprednisolone at
the same dose induced a trend to increases of blood glu-
cose in the two days following intra-articular injection.
Identical observations have been reported with the same
and other depot steroids [1-3]. In most studies, the peak
of glycaemia was reached within 48 h and declined
rapidly afterwards [2,3]. This could not be confirmed
since, in our study, the observation was limited to 2
days after the injections. Most authors mentioned great
individual variations as in our work. The small number
of patients included in our study does not permit us to
determine the causes of such differences. It could be
due to the location of the joint infiltrated [knee,
shoulder] and the type of arthropathy [inflammatory
versus degenerative one].
The absence of blood glucose modification after epi-
dural injection correlated well with the very low urin-
ary excretion of the drug. Indeed the mean excretion
was about ten times less than that observed in our
patients after intra-articular infiltration and in a pre-
vious study [7] after intra-articular or intra muscular
injections. These results suggest that following epidural
injections, methylprednisolone remains mostly locally
in the epidural space and only small amounts enter the
Figure 3 Urinary excretion rate of methylprednisolone after the infiltrations.
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the literature as how corticosteroids injected in the
epidural space are metabolized. The synovial mem-
brane particularly when inflamed probably does not
behave like the epidural membrane and the volume of
dilution in the epidural space is much larger than in
most synovial cavities.
After intra-articular injections, we observed important
individual variations of urinary excretion which could in
part explain the various glycaemic profiles. These varia-
tions cannot be explained by the localisation of the
injections since 3 out of 4 patients were infiltrated in to
the knee. They have been found with other steroid com-
pounds but anyhow in most patients the urinary excre-
tions remain much higher than the ones observed after
epidural infiltrations [9,10].
There are several limitations to this study. First the
product used: acetate of methylprednisolone. Although
it has been the most intensively studied steroid com-
pound in epidural injections [14] is no longer officially
recommended in some countries (Frances, Switzerland).
This restriction is however also extended to most depot
steroid because of a potential although poorly documen-
ted link between injections and rare cases of arachnoidi-
tis. The second is the small number of patients
included. However, in the epidural group, the results
either for the glycaemic profile or the urinary excretion
rate are so convergent that reliable conclusions can rea-
sonably be drawn. Moreover the presence of diabetes
does not influence urinary excretion, very low in all the
patients. This is not the case in the intra-articular infil-
trated groups. Potential causes of the discrepancies
between patients in the post-injection glycaemic profile
have been mentioned above. The same remarks can be
made for urinary excretion rate. Moreover, as the
patients infiltrated in the two parts of the study were
not strictly identical no individual correlation between
glycaemia and urinary excretion is feasible. For all these
reason no definite conclusion about the risk of diabetic
decompensation after an intra-articular at an individual
level can be made.
In conclusion our data have shown that epidural injec-
tion with methylprednisolone can be considered as safe
in diabetic patients. Further extensive studies are needed
to draw similar conclusions after intra-articular
injection.
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